For the Quarter Ending September 2025
APAC
• In South Korea, the Metformin HCL Price Index fell by 14.17% quarter-over-quarter, driven by excess inventories.
• The average Metformin HCL price for the quarter was approximately USD 4006.33/MT, reflecting subdued purchasing activity.
• Metformin HCL Spot Price weakened as Asian export offers softened and landed costs declined, pressuring domestic margins.
• Metformin HCL Price Forecast shows modest volatility with alternating mild declines and brief recoveries through near term.
• Metformin HCL Production Cost Trend eased due to lower raw material costs and favourable USD-KRW movements reducing import expenses.
• Metformin HCL Demand Outlook remains weak with downstream pharmaceuticals and API manufacturers deferring restocking amid ample inventories.
• Export volumes stayed steady while domestic suppliers discounted stock, keeping the Metformin HCL Price Index under downward pressure.
• Major supplier production remained stable, but elevated distributor inventories and cautious procurement constrained upside momentum.
Why did the price of Metformin HCL change in September 2025 in APAC?
• Ample import supplies and discounted Asian export offers increased available volumes, reducing landed costs and price pressure.
• High domestic inventories prompted buyers to delay orders, suppressing procurement and weakening short term demand.
• Lower raw material costs and favourable USD KRW exchange reduced production and import costs, offset slightly by freight.
Europe
• In Germany, the Metformin Price Index fell by 13.08% quarter-over-quarter, driven by import cuts and inventory overhang.
• The average Metformin price for the quarter was approximately USD 4085.33/MT amid subdued procurement activity.
• Metformin Spot Price weakness reflected discounted Asian offers and cautious German buyers delaying replenishment orders.
• Metformin Price Forecast suggests marginal volatility as end-user inquiries slowly recover and inventories normalize gradually.
• Metformin Production Cost Trend benefited from weaker USD and Asian offers, partially offset by freight.
• Metformin Demand Outlook remains muted, keeping Metformin Price Index pressured amid weak pharmaceutical procurement activity.
• Elevated inventories and steady export flows constrained trading, limiting any uptick in Metformin Spot Price.
• Major producers ran steady volumes, limiting disruption risk and supporting balanced Metformin Price Index dynamics.
Why did the price of Metformin change in September 2025 in Europe?
• Abundant Asian export offers and high domestic inventories reduced procurement urgency, driving Metformin downward pressure.
• Weaker USD lowered import costs, while rising freight rates offset savings for landed Metformin shipments.
• Cautious pharmaceutical procurement and soft downstream consumption constrained buying, sustaining weak Metformin Price Index momentum.
North America
• In the USA, the Metformin Price Index declined quarter-over-quarter, reflecting high inventories and weaker import demand from Asia.
• Metformin Spot Price softened as suppliers offered discounts to clear stock, while U.S. buyers delayed orders amid muted pharmaceutical consumption.
• Metformin Price Forecast indicates limited near-term recovery, with expectations of stabilization as downstream restocking resumes gradually.
• Metformin Production Cost Trend for importers eased with lower Asian export quotations and steady freight costs helping moderate landed expenses.
• Metformin Demand Outlook remains subdued, with healthcare and generic drug manufacturers maintaining cautious procurement patterns.
• Elevated inventories and subdued import activity weighed on Metformin Price Index performance across key distribution hubs.
• Competitive pricing among Asian exporters pressured landed cost margins, keeping Metformin Spot Price constrained in the U.S. market.
• Smooth logistics and consistent shipping schedules ensured supply continuity, minimizing volatility despite the weak demand environment.
Why did the price of Metformin change in September 2025 in North America?
• Ample supply from Asian exporters and existing domestic inventories reduced procurement urgency, pushing prices lower.
• Subdued downstream demand and delayed restocking limited transactional activity, maintaining weak market sentiment.
• Stable freight rates and smoother import operations partially offset cost pressures but were insufficient to support price recovery.
For the Quarter Ending June 2025
North America
• In North America (US), the Price Index for Metformin Hydrochloride (USP, FDA) remained on an upward trajectory in July 2025, maintaining the firm momentum seen since late Q2.
• The Spot Price of Metformin Hydrochloride saw steady gains, supported by reduced inventories among major pharmaceutical formulators and continued challenges in securing bulk imports.
• Why did the price of Metformin Hydrochloride change in July 2025?
• The upward movement was primarily attributed to limited supplier offerings from overseas, strong domestic demand for diabetes therapeutics, and tightening logistics for FDA-grade imports.
• The Production Cost Trend for Metformin Hydrochloride in the US remained elevated, influenced by sustained packaging and labor costs, coupled with increased reliance on higher-priced secondary sourcing channels.
• The Demand Outlook for Metformin Hydrochloride in North America remained strong, underpinned by stable prescription volumes, expanding insurance coverage for generic therapeutics, and restocking by hospital buyers.
• The Price Forecast for Metformin Hydrochloride for Q3 2025 indicates further firmness, with expectations of constrained inbound shipments and robust demand from public health procurement programs.
• Importers continued to face lengthened lead times for high-purity Metformin Hydrochloride, resulting in gradual buildup of procurement backlogs among smaller US formulators.
• Market participants reported increased competitiveness in securing forward contracts, with several buyers seeking alternative FDA-approved suppliers to ensure continuity.
• The relatively slow customs clearance and regulatory documentation processes for bulk pharmaceutical ingredients added to lead time challenges across the import cycle.
• The firm Q3 outlook for Metformin Hydrochloride in the US also stems from seasonal upticks in production schedules and pre-holiday order placements from large distribution chains.
Europe
• In Europe (Germany), the Price Index for Metformin Hydrochloride (USP, FDA) CFR Hamburg rose in July 2025, marking a 2.36% increase over the previous month after three months of price decline.
• The Spot Price of Metformin Hydrochloride in Germany increased due to reduced Asian export volumes and improved downstream procurement across the pharmaceutical sector.
• Why did the price change in July 2025?
• The increase was driven by tightening inventory at European ports, limited fresh imports from Asia, and restocking demand by formulation units.
• The Production Cost Trend rose in July, impacted by climbing shipping costs from key producers in China and India, as well as increased packaging and handling charges across the EU.
• The Demand Outlook improved with the onset of Q3 procurement cycles, leading to increased contract activity among German drug formulators.
• The Price Forecast for Q3 2025 indicates a likely continuation of this upward trajectory, supported by constrained global supply and stronger restocking momentum from healthcare manufacturers.
• Additional cost pressure stemmed from regulatory tightening on pharmaceutical-grade API imports, which delayed some shipments and strained local supply.
• Inventory levels remained below the seasonal average across Hamburg and Rotterdam, prompting importers to raise bids to secure short-lead shipments.
• European buyers showed preference for FDA-compliant, USP-grade Metformin Hydrochloride, limiting their supplier base and amplifying price pressure amid lower availability.
• Competitive pressure from non-European sources remained weak as Asian suppliers prioritized domestic fulfillment and high-margin export markets.
APAC
• In APAC (South Korea), the Price Index for Metformin Hydrochloride (USP, FDA) CFR Busan increased in July 2025, marking a reversal from the consistent decline seen in the prior three months.
• The Spot Price of Metformin Hydrochloride rose to USD 4,291/MT in July, reflecting an upward shift driven by limited import supply and restocking by local pharmaceutical manufacturers.
• Why did the price of Metformin Hydrochloride change in July 2025?
• The price increase was driven by tighter export volumes from major Asian producers, currency normalization pressures, and a rebound in short-term procurement activity.
• The Production Cost Trend for Metformin Hydrochloride turned slightly bullish in July, influenced by a rise in freight costs, intermediate raw material prices, and packaging expenses across the Asian region.
• The Demand Outlook for Metformin Hydrochloride in South Korea improved marginally, with downstream formulators ramping up purchases for Q3 delivery cycles amid recovering domestic pharmaceutical output.
• The Price Forecast for Metformin Hydrochloride in August 2025 indicates a potential continuation of the upward trend, supported by depleted inventories and firmer buying interest from end users.
• Availability of Metformin Hydrochloride remained constrained due to export prioritization by Indian and Chinese producers toward higher-margin markets, impacting South Korean shipment volumes.
• Currency movements—specifically the firming of the US Dollar—tempered some of the cost advantages previously enjoyed, affecting Metformin Hydrochloride import economics.
• Despite higher ocean freight, lower inventory levels and improved order consistency supported the recent price rebound of Metformin Hydrochloride in South Korea.
• Public sector procurement and institutional buying further contributed to stronger spot market activity for Metformin Hydrochloride, reinforcing the July price recovery.
For the Quarter Ending March 2025
North America
The U.S. Metformin HCL market experienced notable fluctuations in pricing throughout Q1 2025, driven by a combination of shifting supply and demand dynamics. January began with a significant price drop, as an oversupplied market and weak demand fundamentals prevailed. Aggressive production increases from Asian suppliers, coupled with ample domestic inventories, led to softer pricing conditions. In addition, stable but low international freight rates did little to stimulate renewed demand, causing buyers to adopt a wait-and-see approach in anticipation of further cost reductions.
In February, the market saw a shift as a combination of supply chain disruptions, rising raw material costs, and geopolitical factors such as trade tariffs led to price changes. A 10% tariff on Chinese imports and tighter availability from key suppliers triggered a more competitive procurement environment. Buyers, sensing a tightening of supply, moved quickly to secure inventory, which provided temporary upward momentum. Concurrently, stronger demand from the pharmaceutical sector and a slight improvement in U.S. manufacturing activity contributed to this price fluctuation, with a boost in procurement activity seen throughout the month.
March saw another shift, with prices fluctuating again as oversupply conditions re-emerged. Falling freight costs and ongoing trade uncertainties, including retaliatory tariffs from China, contributed to a more bearish market sentiment. The U.S. Manufacturing PMI showed signs of contraction, and easing inflation led to reduced demand from industrial and downstream sectors. As buyers focused on reducing existing inventories rather than making new purchases, trading volumes remained subdued, reinforcing a downward market pressure. Throughout Q1 2025, the U.S. Metformin HCL market navigated through fluctuations driven by global supply chain disruptions, evolving trade policies, and shifting demand signals from key sectors.
Asia Pacific
The South Korean Metformin HCl market exhibited significant price fluctuations throughout Q1 2025, beginning with a decline in January driven by several key factors. A sluggish demand environment, particularly from the pharmaceutical and healthcare sectors, alongside an oversupply of stock, exerted downward pressure on prices. Buyers had already stocked up ahead of the Lunar New Year, further curtailing fresh orders. Additionally, a strengthening of the South Korean won against the US dollar reduced import costs, contributing to the price reduction. The overall market sentiment was also impacted by rising inflation, reducing consumer purchasing power and pushing prices lower.
In February 2025, Metformin HCl prices continued their downward trajectory due to several market factors. Reduced freight charges from China, along with lower raw material costs and the continued appreciation of the South Korean won, played a significant role in reducing import prices. Weaker industrial activity and rising inflation dampened demand, contributing to the bearish market sentiment.
However, March 2025 saw a notable reversal in pricing trends. Prices surged as rising export prices from China, coupled with increased domestic inflation and growing reliance on imports, pushed procurement costs higher. Strong, consistent demand from the pharmaceutical and healthcare sectors, alongside a rise in national import volumes, helped stabilize the market, supporting the upward price movement. Overall, the South Korean Metformin HCl market showed resilience despite economic challenges, with fluctuations in pricing driven by a mix of international supply dynamics, currency shifts, and demand from key sectors.
Europe
The German Metformin HCl market experienced significant price fluctuations in Q1 2025, starting with a noticeable decline in January. Prices were impacted by volatile consumer sentiment, marked by declining economic and income expectations, and reduced spending inclination. This was further compounded by growing political uncertainty ahead of national elections, which dampened demand, particularly from healthcare and pharmaceutical sectors. Inflationary pressures in the Eurozone, driven by higher energy costs, also squeezed consumer purchasing power, further contributing to the downward price trend. Additionally, expectations of U.S. tariff hikes on Chinese goods led to speculation that Chinese exporters might target European markets, prompting a cautious approach from buyers.
In February 2025, Metformin HCl prices in Germany continued to slide, driven by oversupply conditions, weak downstream demand, and reduced freight costs from China. An excess of inventory from both local suppliers and imports from China pressured prices downward. The depreciation of the Euro against the US Dollar further increased procurement costs, prompting a shift toward more cautious, need-based buying strategies. Additionally, rising inflation and growing unemployment dampened consumer purchasing power, which led to further price reductions.
However, March 2025 saw a significant reversal, with prices rising due to increased export prices from China, driven by higher production costs. Domestic factors also contributed to the upward movement, with a slight recovery in industrial activity reflected in Germany’s Manufacturing PMI. Easing inflation and improved purchasing power from downstream sectors, particularly pharmaceuticals and nutraceuticals, supported stable demand. Despite lower freight rates from China, the overall market remained affected by currency volatility and rising procurement costs, keeping the upward price momentum intact.
Throughout Q1 2025, the German Metformin HCl market was characterized by fluctuating demand, geopolitical uncertainty, and macroeconomic pressures, leading to volatile price movements. The interplay of supply chain dynamics, inflationary trends, and industrial recovery shaped the overall market conditions.
For the Quarter Ending December 2024
North America
In the fourth quarter of 2024, Metformin HCL prices in the United States experienced notable volatility, driven by a variety of shifting market conditions. In October, prices rose, largely due to increased demand following the Federal Reserve's interest rate cuts, which boosted consumer confidence. However, supply chain disruptions, including ongoing port congestion, labor strikes, and the looming threat of tariff hikes under President-elect Donald Trump, placed significant strain on the balance of supply and demand, further elevating prices.
By November, the market shifted as demand began to soften, largely due to concerns over inflation and the persistence of high interest rates. The stronger U.S. dollar helped reduce import costs, while the resolution of the International Longshoremen's Association (ILA) strike helped alleviate some of the logistical bottlenecks. With ample inventories on hand, suppliers had the flexibility to lower prices, providing some relief to buyers.
In December, the downward trend continued, driven by weakening consumer confidence, a typical seasonal dip in demand, and inventory accumulation in anticipation of expected labor strikes and the Chinese Lunar New Year. Heightened inflation concerns and uncertainty over tariffs made buyers more cautious, while the combination of a well-supplied market and competitive pricing further pressured prices downward. Overall, Q4 2024 was marked by significant price fluctuations for Metformin HCL, ultimately ending with a downward trend as the quarter concluded.
Asia Pacific
In the fourth quarter of 2024, the Metformin HCL market in China experienced significant price volatility, influenced by a variety of economic factors and market trends. In October, prices saw a slight increase, driven by a rebound in the manufacturing sector, supported by government stimulus measures. This recovery, alongside rising domestic and export demand fueled by monetary easing and a depreciating yuan, led to improved consumer confidence. As external orders surged, suppliers raised prices in response to the heightened demand.
However, the market dynamics shifted in November, as the market was faced with an oversupply. High inventory levels, weak domestic demand, and subdued international orders, particularly from the U.S. and Europe, led to a reversal of the price increases. Additionally, falling crude oil prices reduced production costs, prompting manufacturers to lower their prices to remain competitive in a slowing market.
In December, the downward trend continued as consumer demand remained tepid amid ongoing disinflationary pressures in China. Pharmaceutical companies and international buyers revised their procurement strategies, leading to weaker overall demand. Moreover, reduced foreign orders during the holiday season left suppliers with excess stock, forcing them to lower prices further in an attempt to clear out inventory before the year-end. Overall, Q4 2024 saw a shift from initial price increases to declines, driven by fluctuating demand and evolving market conditions.
Europe
During the fourth quarter of 2024, Metformin HCL prices in Germany followed a volatile trajectory. In October, prices experienced a significant increase, supported by a boost in business sentiment driven by expectations of economic recovery and the European Central Bank's third interest rate cut to 3.25%. This monetary easing encouraged both consumer spending and business investment. Concurrently, ongoing disruptions in supply chains at Hamburg's ports, along with proactive inventory accumulation, further pushed prices higher.
However, by November, the market outlook shifted as demand from end-user sectors softened and inflationary pressures began to ease. A noticeable decrease in consumer spending and retail activity, combined with a 1.9% decline in energy costs, lowered production expenses, allowing suppliers to reduce prices in order to stay competitive.
In December, the downward price trend persisted, driven by continued weak demand from key industries, cautious purchasing behavior due to lingering inflation concerns, and increased import costs caused by the depreciation of the euro. Higher inventory levels and efforts to clear stock before the year-end further pressured prices down. Additionally, harsh winter weather disrupted logistics, dampening consumer activity even further. In conclusion, Q4 2024 reflected a shift from early optimism to a more cautious economic outlook, leading to a volatile yet generally declining pricing trend.
